Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Efmitermant alfa (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Acceleron Pharma
- 11 May 2022 Results published in the Neurology
- 01 May 2020 Results evaluating the effects of ACE-083 injected into the tibialis anterior (TA) muscles of subjects with CMT1 or CMTX and mild-moderate ankle dorsiflexion weakness presented at the 72nd Annual Meeting of the American Academy of Neurology
- 09 Mar 2020 According to an Acceleron Pharma media release, Acceleron plans to present results of this study at the American Academy of Neurology Annual Meeting in April